Twist Bioscience Corporation Stock Issued During Period, Value, New Issues
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- Twist Bioscience Corporation stock issued during period, value, new issues for the quarter ending 2026-06-30 was $3.75M.
- Twist Bioscience Corporation stock issued during period, value, new issues for the quarter ending 2026-03-31 was $10.00M.
- Twist Bioscience Corporation stock issued during period, value, new issues for the quarter ending 2022-09-30 was -$2.00K.
- Twist Bioscience Corporation stock issued during period, value, new issues for the quarter ending 2022-06-30 was $6.00K.
- Twist Bioscience Corporation stock issued during period, value, new issues for fiscal 2022 was $269.82M, a 16.69% decline from fiscal 2021.
- Twist Bioscience Corporation stock issued during period, value, new issues for fiscal 2021 was $323.86M, a 9.57% increase from fiscal 2020.
- Twist Bioscience Corporation stock issued during period, value, new issues for fiscal 2020 was $295.56M, a 92.11% increase from fiscal 2019.
- Twist Bioscience Corporation stock issued during period, value, new issues for fiscal 2019 was $153.85M.
| Period end | Stock Issued During Period, Value, New Issues 3 month | Stock Issued During Period, Value, New Issues 12 month |
|---|---|---|
| 2026-06-30 | $3.75M 10-Q · filed 2026-08-03 | |
| 2026-03-31 | $10.00M 10-Q · filed 2026-05-04 | |
| 2022-09-30 | -$2.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-11-18 | $269.82M 10-K · filed 2024-11-18 |
| 2022-06-30 | $6.00K 10-Q · filed 2023-08-07 | |
| 2022-03-31 | $269.82M 10-Q · filed 2023-05-08 | |
| 2021-09-30 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2023-11-21 | $323.86M 10-K · filed 2023-11-21 |
| 2021-06-30 | -$26.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-08-08 | $323.74M derived: sum of 4 quarters · filed 2023-06-05 |
| 2021-03-31 | $36.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-05-06 | $431.28M derived: sum of 4 quarters · filed 2023-06-05 |
| 2020-12-31 | $323.85M 10-Q · filed 2022-02-09 | $617.39M derived: sum of 4 quarters · filed 2023-06-05 |
| 2020-09-30 | -$117.00K derived: 10-K/A 12 month − 10-Q 9 month · filed 2023-06-05 | $295.56M 10-K/A · filed 2023-06-05 |
| 2020-06-30 | $107.51M 10-Q · filed 2021-08-09 | $295.68M derived: sum of 4 quarters · filed 2021-11-23 |
| 2020-03-31 | $186.15M 10-Q · filed 2021-05-07 | $272.43M derived: sum of 4 quarters · filed 2021-11-23 |
| 2019-12-31 | $2.02M 10-Q · filed 2021-02-09 | $86.28M derived: sum of 4 quarters · filed 2021-11-23 |
| 2019-09-30 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2021-11-23 | $153.85M 10-K · filed 2021-11-23 |
| 2019-06-30 | $84.25M 10-Q · filed 2020-08-12 | |
| 2019-03-31 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2020-05-13 | |
| 2018-12-31 | $69.60M 10-Q · filed 2020-02-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |